{
    "Clinical Trial ID": "NCT00217399",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Sorafenib and Anastrozole",
        "  All patients receive sorafenib and anastrozole."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed breast cancer",
        "  Metastatic disease",
        "  Measurable disease, defined as >=1 unidimensionally measurable lesion, including >= 1 of the following:",
        "  Lesion >= 10 mm on CT scan (5 mm sections)",
        "  Lesion >= 20 mm on CT scan or MRI (10 mm sections)",
        "  Bone disease that is >= 10 mm on MRI",
        "  Lytic bone lesions that are >= 10 mm on CT scan (with 5 mm sections) OR >= 20 mm on plain film or CT scan (with 10 mm sections)",
        "  Lesion >= 10 mm on physical exam",
        "  Patients must have received >= 1 prior aromatase inhibitor in either the adjuvant or metastatic setting and must have had either disease recurrence or disease progression on a prior aromatase inhibitor therapy",
        "  No brain metastases diagnosed within the past 6 months OR previously untreated brain metastases",
        "  Estrogen receptor-positive and/or progesterone receptor-positive, defined as > 1% staining by immunohistochemistry or > 10 fmol/mg of protein by radio-ligand dextran-coated steroid binding assay",
        "  Postmenopausal, as defined by 1 of the following:",
        "  Prior bilateral oophorectomy",
        "  No menses for >= 12 months in patients with an intact uterus",
        "  Follicle-stimulating hormone (FSH) in postmenopausal range in patients < 60 years of age who have had a prior hysterectomy or have been amenorrheic for >= 3 months",
        "  Age >= 60 years",
        "  Pre- or perimenopausal patients receiving monthly injections of goserelin at a dose of 3.6 mg are eligible",
        "  ECOG 0-2",
        "  More than 3 months",
        "  Absolute neutrophil count >= 1,500/mm3 Platelet count >= 100,000/mm3 No bleeding diathesis",
        "  Bilirubin =< 1.5 times upper limit of normal (ULN AST and ALT =< 2.5 times ULN",
        "  Systolic blood pressure (BP) < 150 mm Hg and diastolic BP < 100 mm Hg on at least one reading prior to study entry No uncontrolled hypertension",
        "  None of the following within the past 6 months:",
        "  Symptomatic congestive heart failure",
        "  Unstable angina pectoris",
        "  Myocardial infarction",
        "  Cardiac arrhythmia with hemodynamic compromise",
        "  Not pregnant or nursing",
        "  Able to swallow oral medication",
        "  No known HIV positivity",
        "  No ongoing or active infection",
        "  No psychiatric illness or social situation that would preclude study compliance",
        "  No other active invasive malignancy within the past 5 years except nonmelanoma skin cancer or treated carcinoma in situ of the cervix",
        "  No other uncontrolled illness",
        "  More than 4 weeks since prior chemotherapy",
        "  No more than 2 prior chemotherapy regimens for metastatic disease",
        "  At least 8 weeks since prior anastrozole therapy",
        "  Concurrent steroids allowed if dose is stable",
        "  More than 4 weeks since prior radiotherapy",
        "  More than 4 weeks since prior major surgery",
        "  Recovered from prior therapy",
        "  No prior sorafenib",
        "  No concurrent therapeutic anticoagulation",
        "  Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided PT and PTT are =< 1.5 times ULN",
        "  No concurrent agents that may interact with sorafenib, including any of the following:",
        "  Hypericum perforatum (St. John's wort)",
        "  Rifampin",
        "  P450 CYP3A4 enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or phenobarbital)",
        "  No other concurrent investigational agents",
        "Exclusion Criteria:",
        "  estrogen receptor status unknown",
        "  history of myocardial infarction within 6 months",
        "  performance status 3",
        "  performance status 4",
        "  premenopausal",
        "  progesterone receptor status unknown",
        "HIV positive"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Complete Response + Partial Response + Stable Disease > 24 Weeks",
        "  Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.",
        "  A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks.",
        "  Time frame: 24 weeks",
        "Results 1: ",
        "  Arm/Group Title: Sorafenib and Anastrozole",
        "  Arm/Group Description: All patients receive sorafenib and anastrozole.",
        "  Overall Number of Participants Analyzed: 35",
        "  Measure Type: Number",
        "  Unit of Measure: participants  35"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 12/35 (34.29%)",
        "  hand-foot syndome * 12/35 (34.29%)"
    ]
}